Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYNT08
|
|||
| Drug Name |
KM-819
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 1 | [1] | |
| Company |
Kainos Medicine
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | FAS-associated factor 1 (FAF1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03022799) Phase I, KM-819 in Healthy Subjects for Parkinson's Disease. U.S. National Institutes of Health. | |||
| REF 2 | A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers. Drug Des Devel Ther. 2019 Mar 29;13:1011-1022. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.